CARsgen Therapeutics Holdings Ltd. (HK:2171) has released an update.
CARsgen Therapeutics Holdings Ltd. has presented updated Phase II results for their innovative CAR T-cell therapy zevor-cel and debut Phase I findings for CT071 at the EHA 2024 Annual Congress, signaling advancements in treatments for relapsed/refractory multiple myeloma. The company, a pioneer in CAR T-cell therapies, also highlighted its global efforts to enhance the safety and efficacy of such treatments for hematologic malignancies and solid tumors. These updates reflect CARsgen’s ongoing commitment to addressing the major challenges in CAR T-cell therapy and improving outcomes for cancer patients.
For further insights into HK:2171 stock, check out TipRanks’ Stock Analysis page.
